British Journal of Cancer · 2022 · 18 citations · 22 references
MedicineOncologyUrologyChemotherapyMolecular OncologyUrologic OncologyBiomarkers In Urologic OncologyBladder CancerCancer GenomicsCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsMuscle-invasive Bladder Cancer ImmunotherapyMuscle-invasive Bladder Cancer TherapyPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 InhibitionUrothelial Carcinoma Adjuvant Therapy
22
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations
Life Sciences, Immunology, Oncology +16
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.4K citations · Full text
Medicine, Cancer Biology, Oncology +14
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
E. John Wherry, Sang‐Jun Ha, Susan M. Kaech et al. · Immunity · 2007 · 2.1K citations
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung et al. · Nature · 2020 · 1.9K citations · Full text
Medicine, Immunology, Oncology +17
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Aurélie Kamoun, Aurélien de Reyniès, Yves Allory et al. · European Urology · 2019 · 1.4K citations · Full text